

### **Affluence Commodities Private Limited**

January 08, 2025

Facilities/Instruments	Amount (₹ crore)	Rating <sup>1</sup>	Rating Action
Short Term Bank Facilities	25.00	CARE A4; ISSUER NOT COOPERATING*	Rating continues to remain under `Issuer not cooperating' category

Details of instruments/facilities in Annexure-1.

\*Issuer did not cooperate; based on best available information.

#### **Rationale and key rating drivers**

CARE Ratings Limited (CARE Ratings) had, vide its press release dated February 23, 2018 placed the ratings of Affluence Commodities Private Limited (ACPL) under the 'issuer non-cooperating' category as ACPL had failed to provide information for monitoring of the ratings as agreed to in its Rating Agreement. ACPL continues to be non-cooperative despite repeated requests for submission of information through phone calls and emails dated October 07, 2024, October 17, 2023 and October 27, 2024. In line with the extant Securities and Exchange Board of India (SEBI) guidelines, CARE Ratings has reviewed the rating on the basis of the best available information which however, in CARE's opinion is not sufficient to arrive at a fair rating. The rating on ACPL's instruments will continue to be denoted as 'CARE A4/Issuer not cooperating\*'.

## Users of this rating (including investors, lenders and the public at large) are hence requested to exercise caution while using the above ratings.

#### Analytical approach: Standalone

#### Outlook: Not applicable

#### Detailed description of the key rating drivers:

CARE Ratings has not received any information except the financials for FY23 & FY24 (extracted from the Registrar of Companies [ROC]). At the time of the last rating on November 22, 2023, the following were the weaknesses and strengths (updated for the information available from the ROC).

#### Key weaknesses

#### Small scale of operations

The total income of ACPL has been declined to ₹0.86 crore as on March 31, 2024 from ₹2.22 crore as on March 31, 2023. Additionally, net profit for FY24 declined to ₹0.62 crore from ₹1.43 crore in FY23.

# High dependence on capital markets leading to volatile revenues and profitability coupled with competitive and subdued industry scenario

High dependence on equity capital markets exposes ACPL's business to volatility in stock markets. Income and profitability are expected to be adversely impacted in times of slowdown in the stock markets which in turn depends on the state of the economy. Further, broking business in India is highly competitive owing to presence of many small broking houses along with presence of many large and established players.

#### **Key Strength**

#### Improved in capital structure

The tangible net-worth of ACPL stood at ₹15.66 crore as on March 31, 2024 as compared to ₹14.98 crore as on March 31, 2023. Total debt reduced to ₹0.13 crore as on March 31, 2024 as compared to ₹0.17 crore as on March 31, 2023.

#### **Applicable criteria**

Policy in respect of Non-cooperation by issuer CARE's Policy on Default Recognition Criteria for Non-Banking Financial Companies Financial ratios – Financial Sector

<sup>&</sup>lt;sup>1</sup>Complete definition of the ratings assigned are available at <u>www.careedge.in</u> and other CARE Ratings Ltd.'s publications



#### Short Term Instruments

#### About the company and industry

#### **Industry classification**

Macro-Economic Indicator	Sector	Industry	Basic Industry
Financial Services Financial Services		Capital Markets	Stockbroking & Allied

Affluence Commodities Pvt. Ltd. (ACPL) was incorporated in January 2007 with an objective to provide commodity broking services. The company acquired broking license from Multi Commodity Exchange (MCX) in February 2007 and from National Commodity and Derivative Exchange (NCDEX) in September 2008. ACPL is promoted by Mr. Dhiren M. Shah (who holds 97.89% equity shares as on March 31, 2016) and Mr. Deval J. Shah.

Brief Financials (₹ crore)	March 31, 2022 (A)	March 31, 2023 (A)	March 31, 2024 (A)
Total operating income	(0.65)	2.22	0.86
PAT	(0.88)	1.43	0.62
Interest coverage (times)	-12.17	NM*	-
Total Assets	14.20	15.87	16.64
Net NPA (%)	NA	NA	NA
ROTA (%)	(5.12)	9.52	3.82

A: Audited UA: Unaudited NM: Not meaningful, since Interest expenses is ₹6,500 only; Note: 'the above results are latest financial results available' \* As indicated in the P&L A/C and Schedule there is no bank charges in FY24 as compared to Rs. 6,500 in FY23. Further it may be noted there was no borrowing (ST/LT) in FY24. However, there was a borrowing of Rs. 0.13 lakhs in FY24 from promoter for which no interest been charged.

#### Status of non-cooperation with previous CRA:

Acuite has rated ACPL as Issuer Not Cooperating vide press release dated October 23, 2023 on account of non-cooperation by management.

#### Any other information: Not applicable

Rating history for last three years: Please refer Annexure-2

**Covenants of rated instrument / facility:** Detailed explanation of covenants of the rated instruments/facilities is given in Annexure-3

#### Complexity level of various instruments rated: Annexure-4

Lender details: Annexure-5

#### Annexure-1: Details of instruments/facilities

Name of the Instrument	ISIN	Date of Issuance (DD-MM- YYYY)	Coupon Rate (%)	Maturity Date (DD- MM-YYYY)	Size of the Issue (₹ crore)	Rating Assigned along with Rating Outlook
Non-fund- based - ST- Bank Guarantee		-	-	Not available	25.00	CARE A4; ISSUER NOT COOPERATING*

\*Issuer did not cooperate; based on best available information.



### Annexure-2: Rating history for the last three years

			Current Ratings		Rating History			
Sr. No	No Instrument/Ba	Typ e	Amount Outstandi ng (₹ crore)	Rating	Date(s) and Rating( s) assigne d in 2024- 2025	Date(s) and Rating(s) assigned in 2023-2024	Date(s) and Rating(s) assigned in 2022-2023	Date(s) and Rating(s) assigned in 2021-2022
1	Non-fund-based - ST-Bank Guarantee	ST	25.00	CARE A4; ISSUER NOT COOPERATIN G*	-	1)CARE A4; ISSUER NOT COOPERATIN G* (22-Nov-23)	1)CARE A4; ISSUER NOT COOPERATIN G* (29-Sep-22)	1)CARE A4; ISSUER NOT COOPERATIN G* (18-Aug-21)

\*Issuer did not cooperate; based on best available information.

\*ST- Short term.

## Annexure-3: Detailed explanation of covenants of the rated instruments/facilities: Not applicable

#### Annexure-4: Complexity level of the various instruments rated

Sr. No.	Name of the Instrument	Complexity Level
1	Non-fund-based - ST-Bank Guarantee	Simple

#### **Annexure-5: Lender details**

To view the lender wise details of bank facilities please <u>click here</u>	
---	--

**Note on the complexity levels of the rated instruments:** CARE Ratings has classified instruments rated by it on the basis of complexity. Investors/market intermediaries/regulators or others are welcome to write to care@careedge.in for any clarifications.



#### Contact us

Media Contact	Analytical Contacts
Mradul Mishra	Priyesh Ruparelia
Director	Director
CARE Ratings Limited	CARE Ratings Limited
Phone: +91-22-6754 3596	Phone: 91-22-67543593
E-mail: mradul.mishra@careedge.in	E-mail: Priyesh.ruparelia@careedge.in
Relationship Contact	Geeta Chainani
	Associate Director
Saikat Roy	CARE Ratings Limited
Senior Director	Phone: 91-22-67543447
CARE Ratings Limited Phone: 91-22-6754 3404	E-mail: <u>Geeta.Chainani@careedge.in</u>
E-mail: saikat.roy@careedge.in	Kumer Bisht
· · · · ·	Associate Executive
	CARE Ratings Limited
	E-mail: <u>kumer.bisht@careedge.in</u>

#### About us:

Established in 1993, CARE Ratings is one of the leading credit rating agencies in India. Registered under the Securities and Exchange Board of India, it has been acknowledged as an External Credit Assessment Institution by the RBI. With an equitable position in the Indian capital market, CARE Ratings provides a wide array of credit rating services that help corporates raise capital and enable investors to make informed decisions. With an established track record of rating companies over almost three decades, CARE Ratings follows a robust and transparent rating process that leverages its domain and analytical expertise, backed by the methodologies congruent with the international best practices. CARE Ratings has played a pivotal role in developing bank debt and capital market instruments, including commercial papers, corporate bonds and debentures, and structured credit.

#### **Disclaimer:**

The ratings issued by CARE Ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse, or recall the concerned bank facilities or to buy, sell, or hold any security. These ratings do not convey suitability or price for the investor. The agency does not constitute an audit on the rated entity. CARE Ratings has based its ratings/outlook based on information obtained from reliable and credible sources. CARE Ratings does not, however, guarantee the accuracy, adequacy, or completeness of any information and is not responsible for any errors or omissions and the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE Ratings have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE Ratings or its subsidiaries/associates may also be involved with other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating/outlook assigned by CARE Ratings is, inter-alia, based on the capital deployed by the partners/proprietors and the current financial strength of the firm. The ratings/outlook may change in case of withdrawal of capital, or the unsecured loans brought in by the partners/proprietors in addition to the financial performance and other relevant factors. CARE Ratings is not responsible for any errors and states that it has no financial liability whatsoever to the users of the ratings of CARE Ratings of CARE Ratings do not factor in any rating-related trigger clauses as per the terms of the facilities/instruments, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and triggered, the ratings may see volatility and sharp downgrades.

For the detailed Rationale Report and subscription information,

please visit www.careedge.in